TPExtreme
Value Health . 2025 Aug 21:S1098-3015(25)02521-5. doi: 10.1016/j.jval.2025.07.032. Online ahead of print.PMID: 40848743
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial: TPEx versus EXTREME as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L; collaborators on behalf of the TPExtreme-ECO Group; Bourhis J, Guigay J, Bonastre J.